Introduction/Background Evaluation of the utility of HE4 and CA 125 assays in monitoring treatmen... more Introduction/Background Evaluation of the utility of HE4 and CA 125 assays in monitoring treatment response before and during treatment, based on the treatment regimen used. Methodology CA125 and HE4 levels were determined in 65 ovarian cancer patients FIGO III–IV. 33 patients received surgical treatment before systemic therapy (CHTH) (Group1) and 32 patients received neoadjuvant chemoterapy (NACTH) before surgery (Group2). Determination of markers was performed in serum samples by the Roche: Group1 before treatment, after surgery, after 3 and 6 CHTH; Group2 before treatment, after NACTH, surgery and 6 CHTH. For statistical calculations, the Mann-Whitney and Wilcoxon tests were used. Results HE4 concentrations were significantly higher in patients that were assigned to NACTH both before and after treatment, as compared to HE4 concentrations in group I (P=0.003, P=0.0004). In Group1, after surgery HE4 and CA125 median levels decreased respectively by 67% and 66%, depending on the level of treatment. In Group2, after NACTH, the reduction in marker levels was larger (HE4 84%; CA125 94%). In Group1, a similar decrease in HE4 median by 72% and CA125 by 96% was only observed after 6 CHTH cycles. In Group1, concentrations of HE4 (P=0.001) and CA125 (P=0.003) were significantly lower after surgery vs before treatment and CA125 levels were further reduced, sixth vs third CHTH course. Similar differences were observed in Group2: HE4 (P=0.002) and CA125 (P=0.0001) were significantly lower after NACTH vs. pre-treatment and more reduced after six courses of CHTH: HE4 (P=0.009) and CA125 (P=0.02). Conclusion At the time of the diagnosis, the median levels of markers HE4 and CA125 are significantly different between patients in the group qualified for NACTH and in patients with advanced ovarian cancer. Observed significant changes in pre-treatment serum concentrations, in particular in the case of HE4 in the schema used, confirm their usefulness in treatment monitoring. Disclosure Nothing to disclose.
The aim of this study was to assess the usefulness of neuron-specific enolase (NSE) concentration... more The aim of this study was to assess the usefulness of neuron-specific enolase (NSE) concentrations as a prognostic factor in patients with neuroendocrine neoplasms and to determine the relationship between NSE and clinicopathological features. Serum NSE levels were measured in 179 NEN patients before treatment. It was found that NSE levels in patients with a primary pancreatic location were higher compared to patients with a small intestine lesion (P = 0.015). NSE levels were significantly higher in patients with primary pancreatic location with histological grade G2 compared with the group with low-grade G1 (P = 0.047). Patients with initial liver involvement showed significantly higher NSE levels compared to patients with tumour location in the pancreas (P = 0.009). Statistical analysis confirmed that higher NSE levels were associated with disease progression (P = 0.001) in both the overall study group and in patients with tumours in the pancreas and small intestine. During treatm...
Background: Obesity is an independent prognostic factor and is associated with poorer response to... more Background: Obesity is an independent prognostic factor and is associated with poorer response to oncological treatment of breast cancer. Obesity is associated with shorter overall survival and shorter time to recurrence. Material and methods: The study included 104 breast cancer patients qualified for neoadjuvant chemotherapy. The control group consisted of 40 patients who refused to participate in the study. Consultation before chemotherapy included: author’s diet questionnaire, body composition analysis, nutrition education. After chemotherapy, the effects of the first dietary advice were evaluated. Results: More than half of all women had a BMI above normal before treatment. Analysis of the effects of nutrition education showed a significant improvement in body composition. After education, a slight increase in body weight and a significant decrease in fat mass and fat percentage were observed. In women who did not participate in education, a statistically significantly greater ...
AimsVulvar squamous cell carcinoma (VSCC) spreads early and mainly locally via direct expansion i... more AimsVulvar squamous cell carcinoma (VSCC) spreads early and mainly locally via direct expansion into adjacent structures, followed by lymphatic metastasis to the regional lymph nodes (LNs). In the lymphatic metastasis, cancer cells bearing CXCR4 and ACKR3 (CXCR7) receptors are recruited to the LNs that produce the CXCL12 ligand. Our study aimed to assess the role of the CXCR4/ACKR3/CXCL12 axis in VSCC progression.MethodsTumour and LN tissue samples were obtained from 46 patients with VSCC and 51 patients with premalignant vulvar lesions. We assessed CXCR4, ACKR3 and CXCL12 by immunohistochemistry (IHC) in the tissue samples. Additionally, CXCL12 levels were determined by ELISA in the sera of 23 patients with premalignant lesions, 37 with VSCC and 16 healthy volunteers.ResultsCXCR4 and ACKR3 proteins were virtually absent in vulvar precancers, while in VSCC samples the IHC staining was strong. In the LNs of patients with VSCC, 98% of metastatic cells expressed CXCR4 and 85% expressed...
Further personalization is needed to improve the outcomes of breast cancer treatment. It is neces... more Further personalization is needed to improve the outcomes of breast cancer treatment. It is necessary to find new inexpensive and easily evaluated predictive markers. In this study, we determined serum level of Aurora A (AURKA), thymidine kinase 1 (TK1) and human epidermal growth factor receptor type 3 (HER3) by enzyme immunoassay ELISA. We collected peripheral blood sera of 119 women with breast cancer before neoadjuvant treatment and the control group of 47 randomly selected healthy women. After treatment we analyzed clinical data: age, initial TNM stage, tumor receptors expression: estrogen (ER), progesterone (PGR), epidermal growth factor receptor type 2 (HER2), Ki67, histological malignancy grade, biological subtype, and response to neoadjuvant treatment in residual cancer burden (RCB) classification. Pathologic complete response (PCR) was achieved in 41 patients (34.45%). In univariate analysis patients with higher AURKA levels were more likely to obtain PCR (p=0.039). In mult...
Introduction . The aim of this study was to evaluate the clinical use of the urinary nuclear matr... more Introduction . The aim of this study was to evaluate the clinical use of the urinary nuclear matrix protein 22 (NMP22) assessment in bladder cancer patients. Patients and methods . 98 patients with bladder cancer were examined. All tumours were verified histopathologically. Urine samples were collected before cystoscopy and assayed for NMP22 levels with Diagnostic Products Corporation tests. Urine samples of 15 healthy volunteers served as controls. For the statistical analysis the Mann-Whitney test was employed. Results . Urine NMP22 concentrations were significantly higher (p<0.0003) in patients with bladder cancer than in controls. No significant differences between the NMP22 concentrations in patients with complete remission and patients with recurrent disease were found. Conclusions . Urinary NMP22 is a potential marker for the diagnosis of bladder cancer, but not for the differentiation between disease-free patients and those with recurrent disease.
Introduction . The study aimed to relate serum VEGF and bFGF concentrations to the clinico-pathol... more Introduction . The study aimed to relate serum VEGF and bFGF concentrations to the clinico-pathological and blood parameters of patients with Hodgkin's lymphoma (HL). Patients and methods. Sixty one patients (age 15-63 years, median age 26 years) with pathologically confirmed HL and no EBV infection, treated in the Cancer Centre and Institute of Oncology in Warsaw between 1997 and 2003, were included. Serum cytokine levels were measured by the commercially available kits of R&D Systems, Minneapolis. Normal ranges were assessed in 50 healthy blood donors. For the statistical analyses Mann-Whitney and Kruskall-Wallis tests were employed. Results . Serum VEGF and bFGF levels were found to be significantly higher in HL patients than in normals. Within the patients' group, those with systemic symptoms presented significantly higher concentrations of VEGF and bFGF. However, only bFGF concentrations correlated with the clinical stage of HL. The cytokines studied did not relate to p...
Streszczenie Celem realizowanych badań jest ocena użyteczności klinicznej oznaczania chromogranin... more Streszczenie Celem realizowanych badań jest ocena użyteczności klinicznej oznaczania chromograniny A u chorych z guzami neuroendokrynnymi jelita cienkiego i jelita grubego oraz u chorych na niesekrecyjne nowotwory neuroendokrynne trzustki. Badaną grupę stanowiło 62 chorych na nowotwory neuroendokrynne przewodu pokarmowego. Stężenia chromograniny A oznaczono u 39 chorych z guzami neuroendokrynnymi jelita cienkiego i jelita grubego oraz u 23 chorych na nowotwory neuroendokrynne trzustki nieczynne hormonalnie. Grupę kontrolną stanowiło 10 zdrowych osób. Stężenie chromograniny A oznaczono metodą immunoenzymatyczną ELISA. Do obliczeń statystycznych zastosowano test Manna-Whitneya. W badanej grupie najwyższą medianę stężeń chromograniny A obserwowano u chorych z lokalizacją guza w jelicie cienkim. Podwyższone stężenia chromograniny A stwierdzono u około 50% chorych, w tym u 15 z lokalizacją zmiany w jelicie cienkim, u 3 w jelicie grubym oraz u 10 chorych na nowotwory trzustki. Stwierdzono...
Ws t ęp. W surowicy krwi chorych na nowotwory złośliwe obserwuje się podwyższone stężenia zarówno... more Ws t ęp. W surowicy krwi chorych na nowotwory złośliwe obserwuje się podwyższone stężenia zarówno cytokin, jak i ich rozpuszczalnych receptorów. Głównym źródłem rozpuszczalnych receptorów są komórki nowotworowe, które wykazują większe tendencje do złuszczania receptorów niż komórki prawidłowe. Celem pracy była ocena związku pomiędzy stężeniami rozpuszczalnych receptorów, takich jak: sIL-2Rα, sTNF RI i sTNF RII a wybranymi parametrami kliniczno-patologicznymi i laboratoryjnymi w surowicy krwi chorych na chłoniaka Hodgkina (HL). Pa c j e n c i i m e t o d y. Badaniami objęto 61 chorych z potwierdzonym histopatologicznie chłoniakiem Hodgkina, leczonych w latach 1997-2003 w Centrum Onkologii – Instytucie im. Marii Skłodowskiej-Curie w Warszawie. Badaniami histopatologicznymi wykluczono infekcję wirusem EBV. Cytokiny oznaczano w surowicy krwi metodą immunoenzymatyczną ELISA, zestawami firmy R&D. Zakres normy dla cytokin określano na podstawie badań wykonanych u 50 zdrowych osób. Do anali...
Introduction/Background Evaluation of the utility of HE4 and CA 125 assays in monitoring treatmen... more Introduction/Background Evaluation of the utility of HE4 and CA 125 assays in monitoring treatment response before and during treatment, based on the treatment regimen used. Methodology CA125 and HE4 levels were determined in 65 ovarian cancer patients FIGO III–IV. 33 patients received surgical treatment before systemic therapy (CHTH) (Group1) and 32 patients received neoadjuvant chemoterapy (NACTH) before surgery (Group2). Determination of markers was performed in serum samples by the Roche: Group1 before treatment, after surgery, after 3 and 6 CHTH; Group2 before treatment, after NACTH, surgery and 6 CHTH. For statistical calculations, the Mann-Whitney and Wilcoxon tests were used. Results HE4 concentrations were significantly higher in patients that were assigned to NACTH both before and after treatment, as compared to HE4 concentrations in group I (P=0.003, P=0.0004). In Group1, after surgery HE4 and CA125 median levels decreased respectively by 67% and 66%, depending on the level of treatment. In Group2, after NACTH, the reduction in marker levels was larger (HE4 84%; CA125 94%). In Group1, a similar decrease in HE4 median by 72% and CA125 by 96% was only observed after 6 CHTH cycles. In Group1, concentrations of HE4 (P=0.001) and CA125 (P=0.003) were significantly lower after surgery vs before treatment and CA125 levels were further reduced, sixth vs third CHTH course. Similar differences were observed in Group2: HE4 (P=0.002) and CA125 (P=0.0001) were significantly lower after NACTH vs. pre-treatment and more reduced after six courses of CHTH: HE4 (P=0.009) and CA125 (P=0.02). Conclusion At the time of the diagnosis, the median levels of markers HE4 and CA125 are significantly different between patients in the group qualified for NACTH and in patients with advanced ovarian cancer. Observed significant changes in pre-treatment serum concentrations, in particular in the case of HE4 in the schema used, confirm their usefulness in treatment monitoring. Disclosure Nothing to disclose.
The aim of this study was to assess the usefulness of neuron-specific enolase (NSE) concentration... more The aim of this study was to assess the usefulness of neuron-specific enolase (NSE) concentrations as a prognostic factor in patients with neuroendocrine neoplasms and to determine the relationship between NSE and clinicopathological features. Serum NSE levels were measured in 179 NEN patients before treatment. It was found that NSE levels in patients with a primary pancreatic location were higher compared to patients with a small intestine lesion (P = 0.015). NSE levels were significantly higher in patients with primary pancreatic location with histological grade G2 compared with the group with low-grade G1 (P = 0.047). Patients with initial liver involvement showed significantly higher NSE levels compared to patients with tumour location in the pancreas (P = 0.009). Statistical analysis confirmed that higher NSE levels were associated with disease progression (P = 0.001) in both the overall study group and in patients with tumours in the pancreas and small intestine. During treatm...
Background: Obesity is an independent prognostic factor and is associated with poorer response to... more Background: Obesity is an independent prognostic factor and is associated with poorer response to oncological treatment of breast cancer. Obesity is associated with shorter overall survival and shorter time to recurrence. Material and methods: The study included 104 breast cancer patients qualified for neoadjuvant chemotherapy. The control group consisted of 40 patients who refused to participate in the study. Consultation before chemotherapy included: author’s diet questionnaire, body composition analysis, nutrition education. After chemotherapy, the effects of the first dietary advice were evaluated. Results: More than half of all women had a BMI above normal before treatment. Analysis of the effects of nutrition education showed a significant improvement in body composition. After education, a slight increase in body weight and a significant decrease in fat mass and fat percentage were observed. In women who did not participate in education, a statistically significantly greater ...
AimsVulvar squamous cell carcinoma (VSCC) spreads early and mainly locally via direct expansion i... more AimsVulvar squamous cell carcinoma (VSCC) spreads early and mainly locally via direct expansion into adjacent structures, followed by lymphatic metastasis to the regional lymph nodes (LNs). In the lymphatic metastasis, cancer cells bearing CXCR4 and ACKR3 (CXCR7) receptors are recruited to the LNs that produce the CXCL12 ligand. Our study aimed to assess the role of the CXCR4/ACKR3/CXCL12 axis in VSCC progression.MethodsTumour and LN tissue samples were obtained from 46 patients with VSCC and 51 patients with premalignant vulvar lesions. We assessed CXCR4, ACKR3 and CXCL12 by immunohistochemistry (IHC) in the tissue samples. Additionally, CXCL12 levels were determined by ELISA in the sera of 23 patients with premalignant lesions, 37 with VSCC and 16 healthy volunteers.ResultsCXCR4 and ACKR3 proteins were virtually absent in vulvar precancers, while in VSCC samples the IHC staining was strong. In the LNs of patients with VSCC, 98% of metastatic cells expressed CXCR4 and 85% expressed...
Further personalization is needed to improve the outcomes of breast cancer treatment. It is neces... more Further personalization is needed to improve the outcomes of breast cancer treatment. It is necessary to find new inexpensive and easily evaluated predictive markers. In this study, we determined serum level of Aurora A (AURKA), thymidine kinase 1 (TK1) and human epidermal growth factor receptor type 3 (HER3) by enzyme immunoassay ELISA. We collected peripheral blood sera of 119 women with breast cancer before neoadjuvant treatment and the control group of 47 randomly selected healthy women. After treatment we analyzed clinical data: age, initial TNM stage, tumor receptors expression: estrogen (ER), progesterone (PGR), epidermal growth factor receptor type 2 (HER2), Ki67, histological malignancy grade, biological subtype, and response to neoadjuvant treatment in residual cancer burden (RCB) classification. Pathologic complete response (PCR) was achieved in 41 patients (34.45%). In univariate analysis patients with higher AURKA levels were more likely to obtain PCR (p=0.039). In mult...
Introduction . The aim of this study was to evaluate the clinical use of the urinary nuclear matr... more Introduction . The aim of this study was to evaluate the clinical use of the urinary nuclear matrix protein 22 (NMP22) assessment in bladder cancer patients. Patients and methods . 98 patients with bladder cancer were examined. All tumours were verified histopathologically. Urine samples were collected before cystoscopy and assayed for NMP22 levels with Diagnostic Products Corporation tests. Urine samples of 15 healthy volunteers served as controls. For the statistical analysis the Mann-Whitney test was employed. Results . Urine NMP22 concentrations were significantly higher (p<0.0003) in patients with bladder cancer than in controls. No significant differences between the NMP22 concentrations in patients with complete remission and patients with recurrent disease were found. Conclusions . Urinary NMP22 is a potential marker for the diagnosis of bladder cancer, but not for the differentiation between disease-free patients and those with recurrent disease.
Introduction . The study aimed to relate serum VEGF and bFGF concentrations to the clinico-pathol... more Introduction . The study aimed to relate serum VEGF and bFGF concentrations to the clinico-pathological and blood parameters of patients with Hodgkin's lymphoma (HL). Patients and methods. Sixty one patients (age 15-63 years, median age 26 years) with pathologically confirmed HL and no EBV infection, treated in the Cancer Centre and Institute of Oncology in Warsaw between 1997 and 2003, were included. Serum cytokine levels were measured by the commercially available kits of R&D Systems, Minneapolis. Normal ranges were assessed in 50 healthy blood donors. For the statistical analyses Mann-Whitney and Kruskall-Wallis tests were employed. Results . Serum VEGF and bFGF levels were found to be significantly higher in HL patients than in normals. Within the patients' group, those with systemic symptoms presented significantly higher concentrations of VEGF and bFGF. However, only bFGF concentrations correlated with the clinical stage of HL. The cytokines studied did not relate to p...
Streszczenie Celem realizowanych badań jest ocena użyteczności klinicznej oznaczania chromogranin... more Streszczenie Celem realizowanych badań jest ocena użyteczności klinicznej oznaczania chromograniny A u chorych z guzami neuroendokrynnymi jelita cienkiego i jelita grubego oraz u chorych na niesekrecyjne nowotwory neuroendokrynne trzustki. Badaną grupę stanowiło 62 chorych na nowotwory neuroendokrynne przewodu pokarmowego. Stężenia chromograniny A oznaczono u 39 chorych z guzami neuroendokrynnymi jelita cienkiego i jelita grubego oraz u 23 chorych na nowotwory neuroendokrynne trzustki nieczynne hormonalnie. Grupę kontrolną stanowiło 10 zdrowych osób. Stężenie chromograniny A oznaczono metodą immunoenzymatyczną ELISA. Do obliczeń statystycznych zastosowano test Manna-Whitneya. W badanej grupie najwyższą medianę stężeń chromograniny A obserwowano u chorych z lokalizacją guza w jelicie cienkim. Podwyższone stężenia chromograniny A stwierdzono u około 50% chorych, w tym u 15 z lokalizacją zmiany w jelicie cienkim, u 3 w jelicie grubym oraz u 10 chorych na nowotwory trzustki. Stwierdzono...
Ws t ęp. W surowicy krwi chorych na nowotwory złośliwe obserwuje się podwyższone stężenia zarówno... more Ws t ęp. W surowicy krwi chorych na nowotwory złośliwe obserwuje się podwyższone stężenia zarówno cytokin, jak i ich rozpuszczalnych receptorów. Głównym źródłem rozpuszczalnych receptorów są komórki nowotworowe, które wykazują większe tendencje do złuszczania receptorów niż komórki prawidłowe. Celem pracy była ocena związku pomiędzy stężeniami rozpuszczalnych receptorów, takich jak: sIL-2Rα, sTNF RI i sTNF RII a wybranymi parametrami kliniczno-patologicznymi i laboratoryjnymi w surowicy krwi chorych na chłoniaka Hodgkina (HL). Pa c j e n c i i m e t o d y. Badaniami objęto 61 chorych z potwierdzonym histopatologicznie chłoniakiem Hodgkina, leczonych w latach 1997-2003 w Centrum Onkologii – Instytucie im. Marii Skłodowskiej-Curie w Warszawie. Badaniami histopatologicznymi wykluczono infekcję wirusem EBV. Cytokiny oznaczano w surowicy krwi metodą immunoenzymatyczną ELISA, zestawami firmy R&D. Zakres normy dla cytokin określano na podstawie badań wykonanych u 50 zdrowych osób. Do anali...
Uploads
Papers